	US 12,121,565 B2
	Methods of treatment of specific cancers with NLRP3 inhibitors and anti-PD1/PD-L1 antibodies
Brent Hanks, Durham, NC (US); and Balamayooran Theivanthiran, Durham, NC (US)
Assigned to Duke University, Durham, NC (US)
Filed by Duke University, Durham, NC (US)
Filed on Sep. 14, 2020, as Appl. No. 17/020,164.
Claims priority of provisional application 62/899,965, filed on Sep. 13, 2019.
Prior Publication US 2021/0077582 A1, Mar. 18, 2021
Int. Cl. A61K 38/21 (2006.01); A61K 39/00 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01); C07K 16/28 (2006.01)

CPC A61K 38/215 (2013.01) [A61K 39/39541 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); C07K 16/2827 (2013.01); A61K 2039/505 (2013.01)]

17 Claims

1. A method of treating a cancer in a subject in need thereof the method comprising administering to the subject a therapeutically effective amount of an NLRP3 inhibitor and at least one of an anti-PD-1 antibody and an anti-PD-L1 antibody such that the cancer is treated in the subject, wherein the NLRP3 inhibitor is at least one of MCC950, a miRNA, a siRNA, and an oligonucleotide, and wherein the cancer comprises lung cancer, breast cancer, pancreatic cancer, colorectal cancer or renal cancer.